ArticleEndoscopy international open2025
Prospective study on outcomes of endotherapy for pancreatic divisum in patients of recurrent acute pancreatitis.
Article in Endoscopy international open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Minor papilla endotherapy success rate is highly variable for pancreatic divisum (PD) among recurrent acute pancreatitis (RAP) patients due to frequent relapses. Therefore, we assessed effectiveness and predictors of successful endotherapy. Patients and methods: This was a prospective observational study of patients with RAP who underwent minor papilla sphincterotomy and prophylactic stenting for PD. Technical success was minor papilla cannulation and successful procedure completion. Primary and secondary outcomes were improvement in recurrent episodes of pain with reduction in visual analogue scale (VAS) score > 50% from baseline and occurrence of chronic pancreatitis (CP) at 12 months, respectively. Predictors of success were assessed by logistic regression. Results: Ninety-four patients, with median age (interquartile range) 29.5 years (23.7-40.2); the majority male (62 [65.9%]), successfully underwent endotherapy. Typical clinical presentation was abdominal pain in 87 patients (92.5%). The primary outcome was achieved in 65 patients (69.1%). The average number of endoscopic retrograde cholangiopancreatography (ERCP) sessions was two; technical success was achieved in 88 patients (93.6%). Post-ERCP pancreatitis was the most common adverse event (AE) in 10 patients (10.6%). Signs of CP were seen in 11 patients (11.7%) and mean follow-up period was 12.8 ± 1.3 months. Presence of smoking (adjusted odds ratio [AOR] 0.027, Conclusions: Minor papilla endotherapy for RAP significantly improved VAS scores at 12 months among 69.1% of patients with acceptable AEs. Early CP was seen in 11.7% of patients. (Unique identifier: CTRI/2019/05/019332).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.